Navigation Links
Drug therapy shows significant benefit in treating a leading cause of childhood blindness
Date:2/16/2011

A readily available, inexpensive drug therapy showed a significant benefit in treating premature infants with the worst and historically most difficult-to-treat cases of retinopathy of prematurity.

The results of a multicenter clinical trial led by researchers at The University of Texas Health Science Center at Houston (UTHealth) are published in the Feb. 17 issue of The New England Journal of Medicine.

Retinopathy of prematurity is a leading cause of childhood blindness worldwide. In the immature retina of babies born before 30 weeks' gestational age, the disease results in disorganized growth of retinal blood vessels, which can lead to scarring and retinal detachment.

In this study, Helen A. Mintz-Hittner, M.D., the Alfred W. Lasher, III, Professor in the Department of Ophthalmology and Visual Science at the UTHealth Medical School, and colleagues compared the use of intravitreal bevacizumab, an anti-vascular endothelial growth factor, to conventional laser treatment.

The study investigators treated infants with acute retinopathy of prematurity affecting zone I and posterior zone II the retinal zones with the highest rate of treatment failure.

Data on the outcomes of 143 infants enrolled in the study showed that, among infants with zone I disease, the recurrence rate was 6 percent with intravitreal bevacizumab and 42 percent with conventional laser therapy. The drug therapy resulted in mild anatomical retinal abnormality in just one eye of 31 infants, whereas conventional laser treatment resulted in a mild structural abnormality in 16 eyes and severe abnormality in two eyes of 33 infants.

"When I started working with babies almost 40 years ago, there was nothing we could do for those with retinopathy of prematurity," said Mintz-Hittner, the study's principal investigator. "We've gone from nothing to a real solution. It you are careful and administer this therapy appropriately in stage 3+, you c
'/>"/>

Contact: Meredith Raine
Meredith.Raine@uth.tmc.edu
713-500-3030
University of Texas Health Science Center at Houston
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. U of Alberta researcher discovers potential cancer therapy target
2. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
3. Photodynamic therapy against cancer
4. A loose grip provides better chemotherapy
5. Early tests find nanoshell therapy effective against brain cancer
6. New anti-HIV gene therapy makes T-cells resistant to HIV infection
7. Caffeine energizes cells, boosting virus production for gene therapy applications
8. Nanodisk gene therapy
9. Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy
10. New breathing therapy reduces panic and anxiety by reversing hyperventilation
11. Missing molecules hold promise of therapy for pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug therapy shows significant benefit in treating a leading cause of childhood blindness
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... a multi-institutional study led by Cincinnati Childrens Hospital ... stubborn solid tumor cancers neuroblastoma and peripheral ... inserting instructions to inhibit tissue growth into an ... the February 15 Cancer Research. Malignant ...
... a one-celled, planktonic marine organism, reported today (Thursday, ... telling scientists about the evolutionary changes that accompanied ... animals like ourselves. In the Nature paper ... week, University of California, Berkeley, biologists Nicole King, ...
... the ideal environmentally friendly energy source, it would be a ... that does not pollute our air when burned. That is ... in a new program that uses bacteria and sunlight to ... The project is one of the first to ...
Cached Biology News:Tumor-targeting viral therapy slows neuroblastoma, malignant peripheral nerve sheath tumors 2Genome of marine organism tells of humans' unicellular ancestors 2Genome of marine organism tells of humans' unicellular ancestors 3Genome of marine organism tells of humans' unicellular ancestors 4Project focuses on production of hydrogen from bacteria and sunlight 2Project focuses on production of hydrogen from bacteria and sunlight 3Project focuses on production of hydrogen from bacteria and sunlight 4
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... the promotion of Nick Maroulis, Pharm.D. to the newly ... , In this position, Dr. Maroulis will continue ... the directors of our multi-site pharmacies as the company ... and during that time he has served in many ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
(Date:12/19/2014)... Dec. 19, 2014 Decision Resources Group finds ... at a 12 percent compound annual growth rate through ... aging population and the increasing adoption of dental implants. ... will also spur demand for dental biomaterials because ... and periodontal treatments. Other key findings from ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 ... nation’s leading specialty pharmacies, has an expanded team ... clinical pharmacy consultants for prescriber offices in their ... , “We have a variety of Regional ... example, those specializing in hepatitis C help prescribers ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... 19, 2011 BioRestorative Therapies, Inc. (OTCQB: BRTX) (the "Company"), ... its common stock is now trading on the OTCQB market ... trading symbol for its common stock has been changed from ... and Chief Executive Officer, said, "The commencement of trading using ...
... Sept. 19, 2011 Palatin Technologies, Inc. (NYSE Amex: ... 2011 financial results on Thursday, September 22, 2011 before the ... also conduct a conference call and live audio webcast hosted ... will include discussion of the results of operations in greater ...
... Sept. 19, 2011 The U.S. Patent and Trademark ... to Cenestra Health,s high-purity omega-3 fatty acid formulations and ... range of high-purity omega-3 formulations including ethyl-ester, free fatty ... was issued U.S. Patent No. 7652068, entitled "Omega-3 ...
Cached Biology Technology:BioRestorative Therapies, Inc. Begins Trading Under New Name and Symbol ("BRTX") 2Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 2Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 3
...
...
... Mouse A-20 cells were cultured in RPMI ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
Biology Products: